Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286587256> ?p ?o ?g. }
- W4286587256 endingPage "1778" @default.
- W4286587256 startingPage "1778" @default.
- W4286587256 abstract "Prostate cancer is one of the most common malignant tumors in men. Initially, it is androgen-dependent, but it eventually develops into castration-resistant prostate cancer (CRPC), which is incurable with current androgen receptor signaling target therapy and chemotherapy. Immunotherapy, specifically with immune checkpoint inhibitors, has brought hope for the treatment of this type of prostate cancer. Approaches such as vaccines, adoptive chimeric antigen receptor-T (CAR-T) cells, and immune checkpoint inhibitors have been employed to activate innate and adaptive immune responses to treat prostate cancer, but with limited success. Only Sipuleucel-T and the immune checkpoint inhibitor pembrolizumab are approved by the US FDA for the treatment of limited prostate cancer patients. Prostate cancer has a complex tumor microenvironment (TME) in which various immunosuppressive molecules and mechanisms coexist and interact. Additionally, prostate cancer is considered a “cold” tumor with low levels of tumor mutational burden, low amounts of antigen-presenting and cytotoxic T-cell activation, and high levels of immunosuppressive molecules including cytokines/chemokines. Thus, understanding the mechanisms of immunosuppressive signaling activation and immune evasion will help develop more effective treatments for prostate cancer. The purpose of this review is to summarize emerging advances in prostate cancer immunotherapy, with a particular focus on the molecular mechanisms that lead to immune evasion in prostate cancer. At the same time, we also highlight some potential therapeutic targets to provide a theoretical basis for the treatment of prostate cancer." @default.
- W4286587256 created "2022-07-22" @default.
- W4286587256 creator A5010745050 @default.
- W4286587256 creator A5011012416 @default.
- W4286587256 creator A5028546502 @default.
- W4286587256 creator A5042070203 @default.
- W4286587256 creator A5048249240 @default.
- W4286587256 creator A5086066594 @default.
- W4286587256 creator A5088621070 @default.
- W4286587256 date "2022-07-22" @default.
- W4286587256 modified "2023-10-15" @default.
- W4286587256 title "The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer" @default.
- W4286587256 cites W1489915607 @default.
- W4286587256 cites W1512075435 @default.
- W4286587256 cites W1541394341 @default.
- W4286587256 cites W1556867369 @default.
- W4286587256 cites W1572810235 @default.
- W4286587256 cites W1671560425 @default.
- W4286587256 cites W1701091641 @default.
- W4286587256 cites W1744273349 @default.
- W4286587256 cites W1965512352 @default.
- W4286587256 cites W1976310228 @default.
- W4286587256 cites W1989325997 @default.
- W4286587256 cites W1992088744 @default.
- W4286587256 cites W1996487270 @default.
- W4286587256 cites W1997423100 @default.
- W4286587256 cites W2002895530 @default.
- W4286587256 cites W2007334137 @default.
- W4286587256 cites W2009109655 @default.
- W4286587256 cites W2016732129 @default.
- W4286587256 cites W2018050275 @default.
- W4286587256 cites W2022635468 @default.
- W4286587256 cites W2025664345 @default.
- W4286587256 cites W2029877275 @default.
- W4286587256 cites W2032268859 @default.
- W4286587256 cites W2034162675 @default.
- W4286587256 cites W2037127114 @default.
- W4286587256 cites W2039129728 @default.
- W4286587256 cites W2040017420 @default.
- W4286587256 cites W2046361773 @default.
- W4286587256 cites W2046389285 @default.
- W4286587256 cites W2051025382 @default.
- W4286587256 cites W2052644931 @default.
- W4286587256 cites W2053404124 @default.
- W4286587256 cites W2060672294 @default.
- W4286587256 cites W2063171513 @default.
- W4286587256 cites W2066671159 @default.
- W4286587256 cites W2067147062 @default.
- W4286587256 cites W2072773071 @default.
- W4286587256 cites W2073100248 @default.
- W4286587256 cites W2074884633 @default.
- W4286587256 cites W2080748037 @default.
- W4286587256 cites W2085462535 @default.
- W4286587256 cites W2085596919 @default.
- W4286587256 cites W2086795423 @default.
- W4286587256 cites W2096554723 @default.
- W4286587256 cites W2097419166 @default.
- W4286587256 cites W2099666268 @default.
- W4286587256 cites W2100192212 @default.
- W4286587256 cites W2103959341 @default.
- W4286587256 cites W2105459360 @default.
- W4286587256 cites W2118278569 @default.
- W4286587256 cites W2121934915 @default.
- W4286587256 cites W2122097157 @default.
- W4286587256 cites W2122403898 @default.
- W4286587256 cites W2129313447 @default.
- W4286587256 cites W2130846254 @default.
- W4286587256 cites W2131297695 @default.
- W4286587256 cites W2137545053 @default.
- W4286587256 cites W2149570955 @default.
- W4286587256 cites W2156923287 @default.
- W4286587256 cites W2162211821 @default.
- W4286587256 cites W2168631000 @default.
- W4286587256 cites W2169258216 @default.
- W4286587256 cites W2260118114 @default.
- W4286587256 cites W2263790045 @default.
- W4286587256 cites W2329107713 @default.
- W4286587256 cites W2339653391 @default.
- W4286587256 cites W2417328318 @default.
- W4286587256 cites W2471500324 @default.
- W4286587256 cites W2529707188 @default.
- W4286587256 cites W2560367415 @default.
- W4286587256 cites W2567297230 @default.
- W4286587256 cites W2587889130 @default.
- W4286587256 cites W2604800509 @default.
- W4286587256 cites W2614879170 @default.
- W4286587256 cites W2618554165 @default.
- W4286587256 cites W2625362849 @default.
- W4286587256 cites W2734921510 @default.
- W4286587256 cites W2740938625 @default.
- W4286587256 cites W2743752097 @default.
- W4286587256 cites W2753432434 @default.
- W4286587256 cites W2760742318 @default.
- W4286587256 cites W2767761069 @default.
- W4286587256 cites W2788142646 @default.
- W4286587256 cites W2789620675 @default.
- W4286587256 cites W2792937256 @default.
- W4286587256 cites W2796494566 @default.